LEADER 03052nam  2200601Ia 450 
001 9910141343103321
005 20230801221933.0
010   $a1-280-58787-3
010   $a9786613617705
010   $a1-118-32151-0
010   $a1-118-32150-2
010   $a1-118-32152-9
035   $a(CKB)2670000000159880
035   $a(EBL)865205
035   $a(OCoLC)781862815
035   $a(SSID)ssj0000632269
035   $a(PQKBManifestationID)11374681
035   $a(PQKBTitleCode)TC0000632269
035   $a(PQKBWorkID)10599892
035   $a(PQKB)10232542
035   $a(MiAaPQ)EBC865205
035   $a(EXLCZ)992670000000159880
100   $a20120320d2012      uy         0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 00$aATTD 2011 Year Book $eAdvanced Technologies and Treatments for Diabetes /$fedited by Moshe Phillip, Tadej Battelino
205   $a3rd ed.
210   $aChichester, West Sussex, UK ;$aHoboken, N.J. $cJohn Wiley & Sons$d2012
215   $a1 online resource (298 p.)
300   $aDescription based upon print version of record.
311   $a1-118-27929-8 
320   $aIncludes bibliographical references and index.
327   $aATTD 2011 Yearbook; Contents; List of Contributors; Preface; CHAPTER 1 Self-Monitoring of Blood Glucose; CHAPTER 2 Continuous Glucose Monitoring in 2011; CHAPTER 3 Insulin Pumps; CHAPTER 4 Closing the Loop; CHAPTER 5 New Insulins and Insulin Therapy; CHAPTER 6 New Ways of Insulin Delivery; CHAPTER 7 Using Health Information Technology to Prevent and Treat Diabetes; CHAPTER 8 Technology and Pregnancy; CHAPTER 9 Type 1 Diabetes Mellitus: Immune Intervention; CHAPTER 10 Advances in Exercise, Physical Activity and Diabetes Mellitus
327   $aCHAPTER 11 Diabetes Technology and Treatment in the Paediatric Age GroupCHAPTER 12 Diabetes Technology and the Human Factor; CHAPTER 13 New Medications for the Treatment of Diabetes; Index
330   $aThe traditional agents for controlling the levels of glucose in the blood remain important therapies but they have their downside from the point of view of tolerability and side effects. Moreover, they appear not to be able to counter the natural history deterioration of the disease in terms of the onset of diabetic-related complications. Recent years have seen an influx of new treatment therapies and technologies aimed at achieving better glycaemic control for diabetic patients such as liraglutide (Novo Nordisk) and saxagliptin (BMS/Astra-Zeneca) and insulin pumps, away from the more tradit
606   $aDiabetes$xTreatment
606   $aDiabetics$xRehabilitation
615  0$aDiabetes$xTreatment.
615  0$aDiabetics$xRehabilitation.
676   $a616.462
676   $a616.46206
701   $aPhillip$b Moshe$0993152
701   $aBattelino$b Tadej$0993153
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910141343103321
996   $aATTD 2011 Year Book$92274141
997   $aUNINA